Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Oncology · Hepatocellular Carcinoma

The Biology of HCC: Identifying the Correct Condition

At a Glance

Hepatocellular Carcinoma (HCC) is a primary liver cancer diagnosed by its unique heavy blood flow on imaging, blood markers like AFP, or a biopsy. Accurately distinguishing HCC from other liver masses, such as bile duct cancer or benign tumors, is crucial for determining the correct treatment.

Understanding the biology of Hepatocellular Carcinoma (HCC) helps explain why it behaves the way it does and how doctors distinguish it from other liver conditions. HCC is a cancer that arises directly from hepatocytes, the primary cells of the liver [1].

What Drives HCC Growth?

Cancer occurs when the “instructions” inside a cell become corrupted. In HCC, certain biological features help the tumor grow and sustain itself. One key feature is its vascular supply. HCC is “hypervascular,” meaning it recruits a massive supply of blood from the hepatic artery [2]. This unique, heavy blood flow pattern is often exactly what doctors look for on specialized scans to confirm the diagnosis without a biopsy.

Ruling Out Other Conditions

Because different liver masses require very different treatments, your medical team must rule out “mimics.”

Condition Key Characteristics How It’s Distinguished from HCC
Intrahepatic Cholangiocarcinoma (ICC) Cancer of the bile ducts inside the liver [3]. Often shows higher levels of the CA 19-9 marker rather than AFP [4][5].
Combined HCC-CCA A rare tumor that contains both HCC and ICC cells [6]. Requires a biopsy or very detailed MRI to see both types of tissue [3].
Focal Nodular Hyperplasia (FNH) A benign (non-cancerous) lump that is often a response to abnormal blood flow [7]. On an Eovist MRI, FNH usually “takes up” the contrast dye, while HCC “washes it out” or appears dark [7][2].
Hepatic Adenoma (HCA) A benign tumor often linked to hormone use (like birth control) [8]. Distinguished by specific markers and the absence of cirrhosis [9][8].

The Role of Tumor Markers

Tumor markers are substances found in your blood that can suggest the presence of cancer. They are rarely used alone but are vital pieces of the puzzle.

  • Alpha-fetoprotein (AFP): This is the most common marker for HCC. While a high level (especially over 400 ng/mL) strongly suggests HCC, some patients with HCC have normal AFP levels [10].
  • PIVKA-II (DCP): This is a newer marker that, when combined with AFP, significantly increases the accuracy of a diagnosis [11][12].
  • CA 19-9: This marker is typically associated with bile duct cancer (ICC). If this is high but AFP is low, your doctor may suspect ICC instead of HCC [4].

Pathological Confirmation

If the diagnosis is still unclear after imaging and blood tests, a biopsy (taking a small tissue sample) may be performed. Pathologists use “stains” to identify the cells. Markers like Arginase-1 and Glypican-3 are highly specific for HCC and help confirm that the cancer started in the hepatocytes [13][14].

Common questions in this guide

How do doctors tell the difference between HCC and other liver tumors?
Doctors often use specialized imaging, like an MRI or CT scan, to observe the blood flow patterns in the tumor. Because HCC has a unique, heavy blood supply from the hepatic artery, it often shows a distinct pattern that helps differentiate it from other liver masses without needing a biopsy.
What tumor markers are used to diagnose Hepatocellular Carcinoma?
Tumor markers are substances in the blood that can suggest cancer. For HCC, the most common marker is Alpha-fetoprotein (AFP). A newer marker called PIVKA-II (DCP) is also often used alongside AFP to significantly increase the accuracy of the diagnosis.
Why might my doctor order a liver biopsy if I have a mass?
If imaging and blood tests do not clearly confirm HCC, a biopsy is performed to examine the tissue directly. A pathologist uses specific stains, such as Arginase-1 or Glypican-3, to accurately identify the cancer cells and confirm they started in the liver.
What is Intrahepatic Cholangiocarcinoma (ICC) and how is it different from HCC?
ICC is a type of cancer that starts in the bile ducts inside the liver, rather than the main liver cells. Doctors distinguish it from HCC by looking for different tumor markers, such as high levels of CA 19-9, and reviewing specific features on your imaging scans.
Can benign liver tumors be mistaken for HCC?
Some benign, non-cancerous growths like Focal Nodular Hyperplasia (FNH) or hepatic adenomas can look similar to HCC initially. Doctors tell them apart by observing how they react to specific MRI contrast dyes, checking tumor markers, and evaluating for underlying liver conditions like cirrhosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.In addition to my AFP level, have you checked my PIVKA-II (DCP) levels to help confirm the diagnosis?
  2. 2.How did you rule out other liver lesions, such as Intrahepatic Cholangiocarcinoma or Focal Nodular Hyperplasia (FNH)?
  3. 3.Based on my imaging, does my lesion have a LI-RADS score, and what does that mean for my diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma.

    Younossi ZM, Henry L

    JHEP reports : innovation in hepatology 2021; (3(4)):100305 doi:10.1016/j.jhepr.2021.100305.

    PMID: 34189448
  2. 2

    Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.

    Zech CJ, Ba-Ssalamah A, Berg T, et al.

    European radiology 2020; (30(1)):370-382 doi:10.1007/s00330-019-06369-4.

    PMID: 31385048
  3. 3

    Histological Heterogeneity of Primary Liver Cancers: Clinical Relevance, Diagnostic Pitfalls and the Pathologist's Role.

    Komuta M

    Cancers 2021; (13(12)) doi:10.3390/cancers13122871.

    PMID: 34201284
  4. 4

    Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.

    Zhang X, Huang WJ, Zhang ML, et al.

    BMC gastroenterology 2022; (22(1)):288 doi:10.1186/s12876-022-02348-0.

    PMID: 35668355
  5. 5

    Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.

    Huang XW, Huang Y, Chen LD, et al.

    Journal of medical ultrasonics (2001) 2018; (45(2)):231-241 doi:10.1007/s10396-017-0834-1.

    PMID: 29052791
  6. 6

    The Worst from Both Worlds: cHCC-ICC.

    Seehawer M, D'Artista L, Zender L

    Cancer cell 2019; (35(6)):823-824 doi:10.1016/j.ccell.2019.05.008.

    PMID: 31185207
  7. 7

    Gd-EOB-DTPA enhanced MRI nomogram model to differentiate hepatocellular carcinoma and focal nodular hyperplasia both showing iso- or hyperintensity in the hepatobiliary phase.

    Mao HY, Shen BQ, Zhang JY, et al.

    BMC medical imaging 2024; (24(1)):211 doi:10.1186/s12880-024-01382-6.

    PMID: 39134943
  8. 8

    Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course.

    van Rosmalen BV, Furumaya A, Klompenhouwer AJ, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2021; (41(10)):2474-2484 doi:10.1111/liv.14989.

    PMID: 34155783
  9. 9

    Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma.

    Nguyen TB, Roncalli M, Di Tommaso L, Kakar S

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016; (29(3)):283-92 doi:10.1038/modpathol.2015.162.

    PMID: 26769138
  10. 10

    The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.

    Zhang J, Chen G, Zhang P, et al.

    PloS one 2020; (15(2)):e0228857 doi:10.1371/journal.pone.0228857.

    PMID: 32053643
  11. 11

    Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study.

    Piratvisuth T, Tanwandee T, Thongsawat S, et al.

    Hepatology communications 2022; (6(4)):679-691 doi:10.1002/hep4.1847.

    PMID: 34796691
  12. 12

    Clinical performance of GAAD score, alpha-fetoprotein, and PIVKA-II in diagnosing hepatocellular carcinoma in the Vietnamese cohort.

    Pham TTT, Ho DT, Nguyen TB, Phan HT

    Discover oncology 2025; (16(1)):1813 doi:10.1007/s12672-025-03651-4.

    PMID: 41042291
  13. 13

    Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens.

    Choi WT, Ramachandran R, Kakar S

    Human pathology 2017; (63()):1-13 doi:10.1016/j.humpath.2016.12.025.

    PMID: 28087475
  14. 14

    Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma.

    Nguyen T, Phillips D, Jain D, et al.

    Archives of pathology & laboratory medicine 2015; (139(8)):1028-34 doi:10.5858/arpa.2014-0479-OA.

    PMID: 26230595

This page explains the biology and diagnostic process of hepatocellular carcinoma for educational purposes only. Always consult your hepatologist or oncologist to interpret your specific imaging scans and laboratory results.

Get notified when new evidence is published on Adult hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.